Monoclonal blood group antibodies

Area of Science:

• Immunology
• Hematology
• Biotechnology

Background:

• High-volume blood typing reagents (ABO, RhD) are crucial for transfusion medicine.
• Traditional reagents face limitations in detecting weak blood group sub-groups and variants.
• Monoclonal antibody technology offers potential for improved reagent performance.

Purpose of the Study:

• To evaluate the efficacy of selected monoclonal antibodies in enhancing ABO and RhD blood typing reagents.
• To optimize reagent formulations for improved agglutination intensity and potency.
• To assess the ability of new reagents to detect weak blood group sub-groups and variants.

Main Methods:

• Preparation of monoclonal antibody blends for anti-A, anti-B, and anti-A,B reagents.
• Development of high-titer IgM monoclonal anti-D reagents for RhD typing.
• Combination of IgG (polyclonal) anti-D with IgM anti-D for weak D detection.
• Formulation of monoclonal anti-complement and anti-IgG blends for anti-human globulin reagents.
• Optimization of pH and dilution for monoclonal anti-M and anti-N reagents.

Main Results:

• Blended monoclonal antibodies significantly improve agglutination for slide and tube tests, detecting weak sub-groups like Ax and Bw.
• IgM monoclonal anti-D enables rapid RhD typing but requires enhancement with IgG anti-D for weak D detection.
• Optimized anti-human globulin reagents provide reliable polyspecific testing without false positives.
• Monoclonal anti-M and anti-N reagents require specific pH and dilution adjustments for accurate detection of variants and heterozygotes.

Conclusions:

• Selected monoclonal antibodies are effective in producing high-quality, high-volume blood typing reagents.
• Optimized reagent blends enhance the detection of weak blood group antigens, improving transfusion safety.
• Monoclonal antibody technology represents a significant advancement in blood group serology.